NVCR
NovoCure Limited
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$17.90
+1.46%Year over year
Reported trailing growth
- Revenue
- +11.0%
- EBITDA
- -36.2%
- EBIT
- +10.6%
- EPS
- +16.7%
- Free cash flow
- +73.7%
- Operating cash flow
- +103.3%
Forward estimates
Based on analyst estimates
- Revenue
- +7.3%
- EBITDA
- +39.3%
- EPS
- +30.7%
Three-year CAGR
- Revenue
- +6.8%
- EBITDA
- -8.6%
- EBIT
- +9.8%
- Net income
- +19.2%
- EPS
- +21.8%
- Free cash flow
- -9.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026